{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:37:46Z","timestamp":1790739466639,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CDK4\/6 inhibitors (CDK4\/6i) and oncolytic viruses are promising therapeutic agents for the treatment of various cancers. As single agents, CDK4\/6 inhibitors that are approved for the treatment of breast cancer in combination with endocrine therapy cause G1 cell cycle arrest, whereas adenoviruses induce progression into S-phase in infected cells as an integral part of the their life cycle. Both CDK4\/6 inhibitors and adenovirus replication target the Retinoblastoma protein albeit for different purposes. Here we show that in combination CDK4\/6 inhibitors potentiate the anti-tumor effect of the oncolytic adenovirus XVir-N-31 in bladder cancer and murine Ewing sarcoma xenograft models. This increase in oncolytic potency correlates with an increase in virus-producing cancer cells, enhanced viral genome replication, particle formation and consequently cancer cell killing. The molecular mechanism that regulates this response is fundamentally based on the reduction of Retinoblastoma protein expression levels by CDK4\/6 inhibitors.<\/jats:p>","DOI":"10.1038\/s41467-022-32087-5","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T08:02:47Z","timestamp":1660118567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Targeting the Retinoblastoma\/E2F repressive complex by CDK4\/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-3992","authenticated-orcid":false,"given":"Jana","family":"Koch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5650-4035","authenticated-orcid":false,"given":"Sebastian J.","family":"Schober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3655-6639","authenticated-orcid":false,"given":"Sruthi V.","family":"Hindupur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Sch\u00f6ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-5838","authenticated-orcid":false,"given":"Florian G.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Mantwill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8893-9471","authenticated-orcid":false,"given":"Maximilian","family":"Ehrenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timmy","family":"Hohnecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7269-5433","authenticated-orcid":false,"given":"Katja","family":"Steiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Aichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9361-7947","authenticated-orcid":false,"given":"Roman","family":"Nawroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1196-2323","authenticated-orcid":false,"given":"Per Sonne","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"32087_CR1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/2168479017738979","volume":"52","author":"T Matsuda","year":"2018","unstructured":"Matsuda, T., Karube, H. & Aruga, A. A comparative safety profile assessment of oncolytic virus therapy based on clinical trials. Ther. Innov. Regul. Sci. 52, 430\u2013437 (2018).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"32087_CR2","doi-asserted-by":"crossref","unstructured":"Peter, M. & Kuhnel, F. Oncolytic adenovirus in cancer immunotherapy. Cancers (Basel) 12, 3354 (2020).","DOI":"10.3390\/cancers12113354"},{"key":"32087_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s42490-019-0016-x","volume":"1","author":"J Hong","year":"2019","unstructured":"Hong, J. & Yun, C. O. Overcoming the limitations of locally administered oncolytic virotherapy. BMC Biomed. Eng. 1, 17 (2019).","journal-title":"BMC Biomed. Eng."},{"key":"32087_CR4","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney, J. et al. Randomized, Open-Label Phase II Study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. 36, 1658\u20131667 (2018).","journal-title":"J. Clin. Oncol."},{"key":"32087_CR5","doi-asserted-by":"crossref","unstructured":"Hindupur, S. V. et al. STAT3\/5 inhibitors suppress proliferation in bladder cancer and enhance oncolytic adenovirus therapy. Int. J. Mol. Sci. 21, 1106 (2020).","DOI":"10.3390\/ijms21031106"},{"key":"32087_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.molcel.2020.08.020","volume":"80","author":"SM Rubin","year":"2020","unstructured":"Rubin, S. M., Sage, J. & Skotheim, J. M. Integrating old and new paradigms of G1\/S control. Mol. Cell 80, 183\u2013192 (2020).","journal-title":"Mol. Cell"},{"key":"32087_CR7","doi-asserted-by":"crossref","unstructured":"Narasimha, A. M. et al. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. Elife 3 (2014).","DOI":"10.7554\/eLife.02872"},{"key":"32087_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1042\/BSR20090171","volume":"30","author":"R Suryadinata","year":"2010","unstructured":"Suryadinata, R., Sadowski, M. & Sarcevic, B. Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates. Biosci. Rep. 30, 243\u201355. (2010).","journal-title":"Biosci. Rep."},{"key":"32087_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1128\/MCB.18.2.753","volume":"18","author":"AS Lundberg","year":"1998","unstructured":"Lundberg, A. S. & Weinberg, R. A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin\u2013cdk complexes. Mol. Cell. Biol. 18, 753\u2013761 (1998).","journal-title":"Mol. Cell. Biol."},{"key":"32087_CR10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1053\/j.gastro.2010.01.007","volume":"138","author":"DB Rivadeneira","year":"2010","unstructured":"Rivadeneira, D. B. et al. Proliferative suppression by CDK4\/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology 138, 1920\u20131930 (2010).","journal-title":"Gastroenterology"},{"key":"32087_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-020-00880-8","volume":"13","author":"Q Du","year":"2020","unstructured":"Du, Q. et al. The application and prospect of CDK4\/6 inhibitors in malignant solid tumors. J. Hematol. Oncol. 13, 41 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"32087_CR12","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","volume":"28","author":"S Goel","year":"2018","unstructured":"Goel, S. et al. CDK4\/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 28, 911\u2013925 (2018).","journal-title":"Trends Cell Biol."},{"key":"32087_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccell.2018.03.023","volume":"34","author":"ME Klein","year":"2018","unstructured":"Klein, M. E. et al. CDK4\/6 inhibitors: the mechanism of action may not be as simple as once thought. Cancer Cell 34, 9\u201320 (2018).","journal-title":"Cancer Cell"},{"key":"32087_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.trecan.2016.11.006","volume":"3","author":"ES Knudsen","year":"2017","unstructured":"Knudsen, E. S. & Witkiewicz, A. K. The strange case of CDK4\/6 inhibitors: mechanisms, resistance, and combination strategies. Trends Cancer 3, 39\u201355 (2017).","journal-title":"Trends Cancer"},{"key":"32087_CR15","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1080\/21691401.2019.1670670","volume":"47","author":"T Li","year":"2019","unstructured":"Li, T. et al. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4\/6-cyclin D-Rb-E2F pathway. Artif. Cells Nanomed. Biotechnol. 47, 4001\u20134011 (2019).","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"32087_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.juro.2015.08.082","volume":"195","author":"A Sathe","year":"2016","unstructured":"Sathe, A. et al. CDK4\/6 inhibition controls proliferation of bladder cancer and transcription of RB1. J. Urol. 195, 771\u2013779 (2016).","journal-title":"J. Urol."},{"key":"32087_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/BLC-170105","volume":"3","author":"Q Pan","year":"2017","unstructured":"Pan, Q. et al. CDK4\/6 inhibitors in cancer therapy: a novel treatment strategy for bladder cancer. Bladder Cancer 3, 79\u201388 (2017).","journal-title":"Bladder Cancer"},{"key":"32087_CR18","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1038\/onc.2010.154","volume":"29","author":"JL Dean","year":"2010","unstructured":"Dean, J. L. et al. Therapeutic CDK4\/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 29, 4018\u20134032 (2010).","journal-title":"Oncogene"},{"key":"32087_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.008","volume":"191","author":"F Lynce","year":"2018","unstructured":"Lynce, F., Shajahan-Haq, A. N. & Swain, S. M. CDK4\/6 inhibitors in breast cancer therapy: Current practice and future opportunities. Pharm. Ther. 191, 65\u201373 (2018).","journal-title":"Pharm. Ther."},{"key":"32087_CR20","doi-asserted-by":"publisher","first-page":"7673","DOI":"10.1038\/sj.onc.1209040","volume":"24","author":"AJ Berk","year":"2005","unstructured":"Berk, A. J. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24, 7673\u20137685 (2005).","journal-title":"Oncogene"},{"key":"32087_CR21","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1038\/sj.onc.1204913","volume":"20","author":"PH Gallimore","year":"2001","unstructured":"Gallimore, P. H. & Turnell, A. S. Adenovirus E1A: remodelling the host cell, a life or death experience. Oncogene 20, 7824\u201335. (2001).","journal-title":"Oncogene"},{"key":"32087_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1126\/science.1411535","volume":"258","author":"JR Nevins","year":"1992","unstructured":"Nevins, J. R. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258, 424\u2013429 (1992).","journal-title":"Science"},{"key":"32087_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0092-8674(81)90304-4","volume":"26","author":"JR Nevins","year":"1981","unstructured":"Nevins, J. R. Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell 26, 213\u2013220 (1981).","journal-title":"Cell"},{"key":"32087_CR24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.virol.2008.12.010","volume":"384","author":"JA DeCaprio","year":"2009","unstructured":"DeCaprio, J. A. How the Rb tumor suppressor structure and function was revealed by the study of Adenovirus and SV40. Virology 384, 274\u2013284 (2009).","journal-title":"Virology"},{"key":"32087_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrm827","volume":"3","author":"SM Frisch","year":"2002","unstructured":"Frisch, S. M. & Mymryk, J. S. Adenovirus-5 E1A: paradox and paradigm. Nat. Rev. Mol. Cell Biol. 3, 441\u201352. (2002).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"32087_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev.ge.23.120189.001041","volume":"23","author":"J Flint","year":"1989","unstructured":"Flint, J. & Shenk, T. Adenovirus E1A protein paradigm viral transactivator. Annu. Rev. Genet. 23, 141\u201361. (1989).","journal-title":"Annu. Rev. Genet."},{"key":"32087_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0378-1119(87)90379-9","volume":"58","author":"DA Zajchowski","year":"1987","unstructured":"Zajchowski, D. A., Boeuf, H. & Kedinger, C. E1a inducibility of the adenoviral early E2a promoter is determined by specific combinations of sequence elements. Gene 58, 243\u2013256 (1987).","journal-title":"Gene"},{"key":"32087_CR28","first-page":"5143","volume":"9","author":"JT Bruder","year":"1989","unstructured":"Bruder, J. T. & Hearing, P. Nuclear factor EF-1A binds to the adenovirus E1A core enhancer element and to other transcriptional control regions. Mol. Cell. Biol. 9, 5143\u20135153 (1989).","journal-title":"Mol. Cell. Biol."},{"key":"32087_CR29","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/80474","volume":"6","author":"C Heise","year":"2000","unstructured":"Heise, C. et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134\u20131139 (2000).","journal-title":"Nat. Med."},{"key":"32087_CR30","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","volume":"95","author":"J Fueyo","year":"2003","unstructured":"Fueyo, J. et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl Cancer Inst. 95, 652\u2013660 (2003).","journal-title":"J. Natl Cancer Inst."},{"key":"32087_CR31","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/gt.2009.103","volume":"16","author":"JJ Rojas","year":"2009","unstructured":"Rojas, J. J. et al. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Ther. 16, 1441\u201351. (2009).","journal-title":"Gene Ther."},{"key":"32087_CR32","doi-asserted-by":"publisher","first-page":"10427","DOI":"10.1074\/jbc.M106955200","volume":"277","author":"PS Holm","year":"2002","unstructured":"Holm, P. S. et al. YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J. Biol. Chem. 277, 10427\u201310434 (2002).","journal-title":"J. Biol. Chem."},{"key":"32087_CR33","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/ijc.25783","volume":"129","author":"R Holzmuller","year":"2011","unstructured":"Holzmuller, R. et al. YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. Int. J. Cancer 129, 1265\u201376. (2011).","journal-title":"Int. J. Cancer"},{"key":"32087_CR34","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1172\/JCI43976","volume":"121","author":"CM Connell","year":"2011","unstructured":"Connell, C. M. et al. Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. J. Clin. Investig. 121, 1283\u20131297 (2011).","journal-title":"J. Clin. Investig."},{"key":"32087_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1089\/hum.2018.026","volume":"30","author":"E Lichtenegger","year":"2019","unstructured":"Lichtenegger, E. et al. The oncolytic adenovirus XVir-N-31 as a novel therapy in muscle-invasive bladder cancer. Hum. Gene Ther. 30, 44\u201356 (2019).","journal-title":"Hum. Gene Ther."},{"key":"32087_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-016-0473-1","volume":"36","author":"M Isono","year":"2017","unstructured":"Isono, M. et al. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. J. Exp. Clin. Cancer Res. 36, 1 (2017).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"32087_CR37","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1158\/0008-5472.CAN-03-3741","volume":"64","author":"MM Facchinetti","year":"2004","unstructured":"Facchinetti, M. M. et al. UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1\/cip1) by activation of mitogen-activated protein\/extracellular signal-regulated kinase kinase\/extracellular signal-regulated kinase pathway. Cancer Res. 64, 3629\u20133637 (2004).","journal-title":"Cancer Res."},{"key":"32087_CR38","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/0165-6147(89)90263-0","volume":"10","author":"UT Ruegg","year":"1989","unstructured":"Ruegg, U. T. & Burgess, G. M. Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharm. Sci. 10, 218\u2013220 (1989).","journal-title":"Trends Pharm. Sci."},{"key":"32087_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1042\/bj20031119","volume":"375","author":"D Komander","year":"2003","unstructured":"Komander, D. et al. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem. J. 375, 255\u2013262 (2003).","journal-title":"Biochem. J."},{"key":"32087_CR40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1128\/jvi.71.1.548-561.1997","volume":"71","author":"FD Goodrum","year":"1997","unstructured":"Goodrum, F. D. & Ornelles, D. A. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol. 71, 548\u2013561 (1997).","journal-title":"J. Virol."},{"key":"32087_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/biomedicines2020163","volume":"2","author":"M Vaha-Koskela","year":"2014","unstructured":"Vaha-Koskela, M. & Hinkkanen, A. Tumor restrictions to oncolytic virus. Biomedicines 2, 163\u2013194 (2014).","journal-title":"Biomedicines"},{"key":"32087_CR42","doi-asserted-by":"crossref","unstructured":"Teijeira Crespo, A. et al. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163, 389\u2013398 (2021).","DOI":"10.1111\/imm.13323"},{"key":"32087_CR43","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","volume":"275","author":"JM Bergelson","year":"1997","unstructured":"Bergelson, J. M. et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320\u20131323 (1997).","journal-title":"Science"},{"key":"32087_CR44","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3390\/cancers11050684","volume":"11","author":"N Lypova","year":"2019","unstructured":"Lypova, N. et al. Targeting palbociclib-resistant estrogen receptor-positive breast cancer cells via oncolytic virotherapy. Cancers (Basel) 11, 684 (2019).","journal-title":"Cancers (Basel)"},{"key":"32087_CR45","doi-asserted-by":"publisher","first-page":"6028","DOI":"10.1158\/1078-0432.CCR-18-1256","volume":"24","author":"M Dowless","year":"2018","unstructured":"Dowless, M. et al. Abemaciclib is active in preclinical models of Ewing sarcoma via multipronged regulation of cell cycle, DNA methylation, and interferon pathway signaling. Clin. Cancer Res. 24, 6028\u20136039 (2018).","journal-title":"Clin. Cancer Res."},{"key":"32087_CR46","first-page":"297","volume":"2","author":"E Uzvolgyi","year":"1991","unstructured":"Uzvolgyi, E. et al. Reintroduction of a normal retinoblastoma gene into retinoblastoma and osteosarcoma cells inhibits the replication associated function of SV40 large T antigen. Cell Growth Differ. 2, 297\u2013303 (1991).","journal-title":"Cell Growth Differ."},{"key":"32087_CR47","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1073\/pnas.84.8.2180","volume":"84","author":"I Kovesdi","year":"1987","unstructured":"Kovesdi, I., Reichel, R. & Nevins, J. R. Role of an adenovirus E2 promoter binding factor in E1A-mediated coordinate gene control. Proc. Natl Acad. Sci. USA 84, 2180\u20132184 (1987).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32087_CR48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1073\/pnas.82.2.381","volume":"82","author":"MJ Imperiale","year":"1985","unstructured":"Imperiale, M. J., Hart, R. P. & Nevins, J. R. An enhancer-like element in the adenovirus E2 promoter contains sequences essential for uninduced and E1A-induced transcription. Proc. Natl Acad. Sci. USA 82, 381\u2013385 (1985).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32087_CR49","first-page":"4391","volume":"12","author":"VB Kraus","year":"1992","unstructured":"Kraus, V. B., Moran, E. & Nevins, J. R. Promoter-specific trans-activation by the adenovirus E1A12S product involves separate E1A domains. Mol. Cell. Biol. 12, 4391\u20134399 (1992).","journal-title":"Mol. Cell. Biol."},{"key":"32087_CR50","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/j.1460-2075.1984.tb02066.x","volume":"3","author":"G Winberg","year":"1984","unstructured":"Winberg, G. & Shenk, T. Dissection of overlapping functions within the adenovirus type 5 E1A gene. EMBO J. 3, 1907\u20131912 (1984).","journal-title":"EMBO J."},{"key":"32087_CR51","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1128\/MCB.20.1.363-371.2000","volume":"20","author":"S He","year":"2000","unstructured":"He, S. et al. E2F is required to prevent inappropriate S-phase entry of mammalian cells. Mol. Cell. Biol. 20, 363\u201371. (2000).","journal-title":"Mol. Cell. Biol."},{"key":"32087_CR52","first-page":"3214","volume":"5","author":"P Hearing","year":"1985","unstructured":"Hearing, P. & Shenk, T. Sequence-independent autoregulation of the adenovirus type 5 E1A transcription unit. Mol. Cell. Biol. 5, 3214\u201321. (1985).","journal-title":"Mol. Cell. Biol."},{"key":"32087_CR53","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0168-1702(88)90051-2","volume":"9","author":"GM Glenn","year":"1988","unstructured":"Glenn, G. M. & Ricciardi, R. P. Detailed kinetics of adenovirus type-5 steady-state transcripts during early infection. Virus Res. 9, 73\u201391 (1988).","journal-title":"Virus Res."},{"key":"32087_CR54","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427\u20131438 (2004).","journal-title":"Mol. Cancer Ther."},{"key":"32087_CR55","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658\u2013670 (2012).","journal-title":"Nat. Biotechnol."},{"key":"32087_CR56","doi-asserted-by":"publisher","first-page":"10522","DOI":"10.3390\/ijms221910522","volume":"22","author":"K Mantwill","year":"2021","unstructured":"Mantwill, K. et al. Concepts in oncolytic adenovirus therapy. Int. J. Mol. Sci. 22, 10522 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"32087_CR57","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1158\/1078-0432.CCR-18-0372","volume":"25","author":"LM Guenther","year":"2019","unstructured":"Guenther, L. M. et al. A combination CDK4\/6 and IGF1R inhibitor strategy for Ewing sarcoma. Clin. Cancer Res. 25, 1343\u20131357 (2019).","journal-title":"Clin. Cancer Res."},{"key":"32087_CR58","doi-asserted-by":"publisher","first-page":"e6422","DOI":"10.1371\/journal.pone.0006422","volume":"4","author":"MA Garcia","year":"2009","unstructured":"Garcia, M. A. et al. Activation of NF-kB pathway by virus infection requires Rb expression. PLoS ONE 4, e6422 (2009).","journal-title":"PLoS ONE"},{"key":"32087_CR59","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1128\/jvi.64.5.2103-2109.1990","volume":"64","author":"LS Chang","year":"1990","unstructured":"Chang, L. S. & Shenk, T. The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adeno-associated virus promoters. J. Virol. 64, 2103\u20132109 (1990).","journal-title":"J. Virol."},{"key":"32087_CR60","doi-asserted-by":"publisher","first-page":"e1005415","DOI":"10.1371\/journal.ppat.1005415","volume":"12","author":"Y Zheng","year":"2016","unstructured":"Zheng, Y., Stamminger, T. & Hearing, P. E2F\/Rb family proteins mediate interferon induced repression of adenovirus immediate early transcription to promote persistent viral infection. PLoS Pathog. 12, e1005415 (2016).","journal-title":"PLoS Pathog."},{"key":"32087_CR61","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s13046-019-1322-9","volume":"38","author":"Z Tong","year":"2019","unstructured":"Tong, Z. et al. Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4\/6 inhibition in bladder cancer. J. Exp. Clin. Cancer Res. 38, 322 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"32087_CR62","doi-asserted-by":"publisher","first-page":"8841","DOI":"10.1128\/JVI.00539-11","volume":"85","author":"P Pelka","year":"2011","unstructured":"Pelka, P. et al. Adenovirus E1A directly targets the E2F\/DP-1 complex. J. Virol. 85, 8841\u20138851 (2011).","journal-title":"J. Virol."},{"key":"32087_CR63","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1128\/jvi.68.8.5027-5035.1994","volume":"68","author":"K Helin","year":"1994","unstructured":"Helin, K. & Harlow, E. Heterodimerization of the transcription factors E2F-1 and DP-1 is required for binding to the adenovirus E4 (ORF6\/7) protein. J. Virol. 68, 5027\u20135035 (1994).","journal-title":"J. Virol."},{"key":"32087_CR64","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1002\/1873-3468.13672","volume":"593","author":"P Hidalgo","year":"2019","unstructured":"Hidalgo, P. & Gonzalez, R. A. Formation of adenovirus DNA replication compartments. FEBS Lett. 593, 3518\u20133530 (2019).","journal-title":"FEBS Lett."},{"key":"32087_CR65","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.bbrc.2009.05.094","volume":"385","author":"S Ohashi","year":"2009","unstructured":"Ohashi, S., Atsumi, M. & Kobayashi, S. HSP60 interacts with YB-1 and affects its polysome association and subcellular localization. Biochem. Biophys. Res. Commun. 385, 545\u2013550 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"32087_CR66","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.omto.2019.04.003","volume":"13","author":"V Sivanandam","year":"2019","unstructured":"Sivanandam, V. et al. Oncolytic viruses and immune checkpoint inhibition: the best of both worlds. Mol. Ther. Oncolytics 13, 93\u2013106 (2019).","journal-title":"Mol. Ther. Oncolytics"},{"key":"32087_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01318-2","volume":"22","author":"N Portman","year":"2020","unstructured":"Portman, N. et al. MDM2 inhibition in combination with endocrine therapy and CDK4\/6 inhibition for the treatment of ER-positive breast cancer. Breast Cancer Res. 22, 87 (2020).","journal-title":"Breast Cancer Res."},{"key":"32087_CR68","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1158\/1541-7786.MCR-18-0201","volume":"16","author":"AC Chaikovsky","year":"2018","unstructured":"Chaikovsky, A. C. & Sage, J. Beyond the cell cycle: enhancing the immune surveillance of tumors via CDK4\/6 inhibition. Mol. Cancer Res. 16, 1454\u20131457 (2018).","journal-title":"Mol. Cancer Res."},{"key":"32087_CR69","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel, S. et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature 548, 471\u2013475 (2017).","journal-title":"Nature"},{"key":"32087_CR70","doi-asserted-by":"publisher","first-page":"108944","DOI":"10.1016\/j.celrep.2021.108944","volume":"35","author":"RV Uzhachenko","year":"2021","unstructured":"Uzhachenko, R. V. et al. Metabolic modulation by CDK4\/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Rep. 35, 108944 (2021).","journal-title":"Cell Rep."},{"key":"32087_CR71","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/jpm11050340","volume":"11","author":"FG Klein","year":"2021","unstructured":"Klein, F. G. et al. Combination of talazoparib and palbociclib as a potent treatment strategy in bladder cancer. J. Pers. Med. 11, 340 (2021).","journal-title":"J. Pers. Med."},{"key":"32087_CR72","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0168-1702(95)00071-2","volume":"39","author":"AJ Bett","year":"1995","unstructured":"Bett, A. J., Krougliak, V. & Graham, F. L. DNA sequence of the deletion\/insertion in early region 3 of Ad5 dl309. Virus Res. 39, 75\u201382 (1995).","journal-title":"Virus Res."},{"key":"32087_CR73","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/0092-8674(79)90275-7","volume":"17","author":"N Jones","year":"1979","unstructured":"Jones, N. & Shenk, T. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 17, 683\u2013689 (1979).","journal-title":"Cell"},{"key":"32087_CR74","doi-asserted-by":"publisher","first-page":"8802","DOI":"10.1073\/pnas.91.19.8802","volume":"91","author":"AJ Bett","year":"1994","unstructured":"Bett, A. J. et al. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl Acad. Sci. USA 91, 8802\u20138806 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32087_CR75","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou\u2013Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"32087_CR76","doi-asserted-by":"publisher","first-page":"e1462431","DOI":"10.1080\/2162402X.2018.1462431","volume":"7","author":"DP Enot","year":"2018","unstructured":"Enot, D. P. et al. TumGrowth: an open-access web tool for the statistical analysis of tumor growth curves. Oncoimmunology 7, e1462431 (2018).","journal-title":"Oncoimmunology"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32087-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32087-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32087-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:36:08Z","timestamp":1669296968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32087-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32087"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32087-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"28 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.S.H. is co-founder of XVir Therapeutics GmbH. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4689"}}